Presenting
Action Hotels
Established in 2005, Action Hotels is recognised as a leading developer and owner of economy and midscale hotels in the Middle East, with a growing presence in Australia. Our focus is to introduce quality accommodation at exceptional value in central and convenient locations, wherever we operate. Our strong partnership and long-standing relationships with international hotel operators allow us to diversify our portfolio of hotels and develop the most suitable properties for each market.
Biofrontera
We specialize in dermatology, because the health of your skin is our profession. With our innovative products we would like to cure and protect your skin, while creating value for our investors.
Biofrontera AG operates as an administrative holding company with four wholly-owned subsidiaries, Biofrontera Bioscience GmbH, Biofrontera Pharma GmbH, Biofrontera Development GmbH and Biofrontera Neuroscience GmbH. While the first two cover the operational business of Biofrontera group, the latter allow structured funding of individual clinical development projects. The companies occupy fully equipped, modern lab facilities with sufficient space for growth, an own GMP-certified laboratory and a GMP-certified medicament storage room.
Biofrontera group was founded in 1997 by Prof. Dr. Hermann Lübbert, the current CEO, and is located in Leverkusen, Germany.
Since 2006 Biofrontera is listed in the regulatory market under the ISIN DE0006046113, the company currently employs 46 people.
Magnolia Petroleum
Magnolia Petroleum plc is an AIM quoted oil and gas production company focused on the acquisition, exploitation and development of oil and gas properties primarily located onshore in the United States. Led by a highly skilled management team with over 100 years combined experience in the onshore oil and gas industry, the Company already has interests in approximately 183+ producing properties and over 13,500 net mineral acres in two major project areas, the potentially game-changing and highly productive Bakken shale in North Dakota and the proven Woodford/Mississippi and Hunton formations in Oklahoma.
Motif Bio
Motif Bio is a clinical stage biopharmaceutical company which specializes in developing novel antibiotics designed to be effective against serious and life-threatening infections caused by multi-drug resistant bacteria. Iclaprim is being developed for the treatment of the most common and serious bacterial infections such as acute bacterial skin and skin structure infections (ABSSSI) and hospital acquired bacterial pneumonia (HABP), including those caused by resistant strains such as MRSA (methicillin-resistant Staphylococcus aureus) and MDRSP (multi-drug resistantStreptococcus pneumoniae) that have become prevalent in patients in both the community and hospital settings. Motif is in discussions with pharmaceutical companies and universities to build a pipeline of innovative antibiotics targeting Gram positive and Gram negative bacteria.
